Research progress of graft-versus-host disease after liver transplantation.
- Author:
Xiao-feng TANG
1
Author Information
1. Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
- Publication Type:Journal Article
- MeSH:
Autoantibodies;
therapeutic use;
Graft vs Host Disease;
drug therapy;
prevention & control;
Humans;
Immunosuppressive Agents;
administration & dosage;
Liver Transplantation;
adverse effects;
Methylprednisolone;
administration & dosage;
Receptors, Interleukin-2;
immunology
- From:
Journal of Zhejiang University. Medical sciences
2006;35(4):453-462
- CountryChina
- Language:Chinese
-
Abstract:
Graft-versus-host disease (GVHD) is an uncommon but fatal complication of orthotopic liver transplantation (OLT). The pathogenesis and mechanism of GVHD after OLT remains unclear and the treatment is therefore largely empirical. The prevention of GVHD including avoidance of closely matched human leukocyte antigen donors and old-age recipients is of particular importance because effective treatment is lacking. To reduce immunosuppressants combined with high dose of methylprednisolone and IL-2 receptor antibodies can be applied as a reasonable regime.
